TGFB1 and pulmonary fibrosis: Anti-inflammatory agents targeting pro-inflammatory cytokines, such as TNF-α, IL-1, and TGF-β [263], and anti-fibrotic drugs, including pirfenidone and nintedanib [264,265] have been explored as potential treatments for pulmonary fibrosis in addition to antioxidant therapies.